Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | EYA2 | O00167 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL1840973 | 1.00 | FFAR3 (0.41) | FFAR3CHRM2CHRM4CHRM5CHRM1 | |
| Oxalic Acid SCHEMBL27532528 | 1.00 | FFAR3 (0.41) | FFAR3CHRM2CHRM4CHRM5CHRM1 | |
| Oxalic Acid SCHEMBL28460363 | 0.97 | FFAR3 (0.39) | FFAR3CHRM2CHRM4CHRM5CHRM1 | |
| Oxalic Acid SCHEMBL27615093 | 0.97 | FFAR3 (0.39) | FFAR3CHRM2CHRM4CHRM5CHRM1 | |
| Oxalic Acid SCHEMBL19209492 | 0.91 | ARG1 (0.35) | FFAR3CHRM2CHRM4CHRM5CHRM1 | |
| Oxalic Acid SCHEMBL19209502 | 0.91 | ARG1 (0.35) | FFAR3CHRM2CHRM4CHRM5CHRM1 | |
| Bicarbonate SCHEMBL378701 | 0.89 | FFAR3 (0.44) | FFAR3CHRM2CHRM4CHRM5CHRM1 | |
| Bicarbonate SCHEMBL60768 | 0.89 | FFAR3 (0.44) | FFAR3CHRM2CHRM4CHRM5CHRM1 | |
| Pyruvate SCHEMBL21145028 | 0.87 | CHRM2 (0.41) | FFAR3CHRM2CHRM4CHRM5CHRM1 | |
| Oxalic Acid SCHEMBL28576882 | 0.87 | TDP1 (0.43) | FFAR3CHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109276569-A | A kind of stable crystal form pharmaceutical composition and its preparation method and application | 四川海思科制药有限公司 | 2019-01-29 | — | — | CN | claimed |
| CN-102391140-B | Preparation method of N-(2- indanyl) amino acid alkyl ester | HUNAN FANGSHENG PHARMACEUTICAL CO LTD | 2014-08-06 | — | — | CN | claimed |
| CN-102391140-A | Preparation method of N-(2- indanyl) amino acid alkyl ester | HUNAN FANGSHENG PHARMACEUTICAL CO LTD | 2012-03-28 | — | — | CN | claimed |
| EP-1861364-B1 | PREPARATION OF AN ATORVASTATIN INTERMEDIATE USING A PAAL-KNORR CONDENSATION | C P PHARMACEUTICALS INTERNAT C V (US) | 2011-05-11 | — | — | EP | claimed |
| JP-2008533128-A | — | — | 2008-08-21 | — | — | JP | claimed |
| EP-1861364-A1 | PREPARATION OF AN ATORVASTATIN INTERMEDIATE USING A PAAL-KNORR CONDENSATION | Pfizer Science and Technology Ireland Limited (IE) | 2007-12-05 | — | — | EP | claimed |
| WO-2006097909-A1 | PREPARATION OF AN ATORVASTATIN INTERMEDIATE USING A PAAL-KNORR CONDENSATION | PFIZER SCIENCE AND TECHNOLOGY IRELAND LIMITED (IE) | 2006-09-21 | — | — | WO | claimed |
| US-20260062375-A1 | AMINE SEPARATION METHOD | DAICEL CORPORATION (JP) | 2026-03-05 | — | — | US | disclosed |
| EP-4578848-A1 | AMINE SEPARATION METHOD | Daicel Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025132334-A1 | RESISTS USING PFAS FREE PAGS | MERCK PATENT GMBH (DE) | 2025-06-26 | — | — | WO | disclosed |
| CN-119768389-A | Method for separating amine | 株式会社大赛璐 | 2025-04-04 | — | — | CN | disclosed |
| CN-117321061-A | Sodium difluoro oxalate borate, and preparation method and application thereof | 时代思康新材料有限公司 | 2023-12-29 | — | — | CN | disclosed |
| WO-2023245662-A1 | SODIUM DIFLUORO(OXALATO)BORATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 时代思康新材料有限公司 | 2023-12-28 | — | — | WO | disclosed |
| US-6677278-B1 | PRODUCED BY SPRAY PYROLYSIS THAT ARE THEN FURTHER HEAT TREATED SUCH THAT THEY SHOW CONSIDERABLE ADVANTAGE IN FORMING THE PB-BI- SR-CA-CU-O 2-2-2-3 SUPERCONDUCTING PHASE OVER POWDERS PRODUCED USING OTHER ROUTES | MERCK PATENT GMBH (DE) | 2004-01-13 | — | — | US | disclosed |
| US-20030222577-A1 | Full color organic light-emitting display device | RITDISPLAY CORPORATION (TW) | 2003-12-04 | — | — | US | disclosed |
| US-20030222576-A1 | Full color organic light-emitting display device | RITDISPLAY CORPORATION (TW) | 2003-12-04 | — | — | US | disclosed |
| US-20030091838-A1 | Composition for film formation, method of film formation, and silica-based film | JSR CORPORATION (JP) | 2003-05-15 | — | — | US | disclosed |
| US-5206215-A | PROCESS FOR OBTAINING PRECURSORS FOR HIGH CRITICAL TEMPERATURE SUPERCONDUCTOR CERAMICS COMPRISING A FIRST AND SECOND PRECIPITATION | ALCATEL ALSTHOM COMPAGNIE GENERALE D'ELECTRICITE (FR) | 1993-04-27 | — | — | US | disclosed |
| US-5103042-A | METHOD FOR REDUCING UNSATURATION OF POLYETHERS | THE DOW CHEMICAL COMPANY (US) | 1992-04-07 | — | — | US | disclosed |
| EP-0458262-A2 | Method for reducing unsaturation of polyethers | THE DOW CHEMICAL COMPANY (US) | 1991-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062375-A1 | AMINE SEPARATION METHOD | SLC7A1, SAMM50, PNMT | FFAR3 1506/4885CHRM2 6/4885CHRM4 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.